Introduction
Immunotherapy is a promising modality in the treatment of cancer. Treatment with cytokines, sometimes in combination with adoptive transfer of immunocompetent cells, is successful in several animal models as well as in patients with different types of malignancies, especially renal cell carcinoma or melanoma [4, 18, 21, 28, 32] . The cytokines interleukin-2, the interferons, and tumour necrosis factor o~ (TNFcz) have been most frequently studied. We have been working for some years with interferon 7 and TNF~ in various experimental tumour models [8, 14, 15, 25] .
TNF~ appeared to have a growth-inhibiting effect in some models [14, 15] , but in those models resembling the clinical situation best, i.e. liver metastases of colon carcinoma, a significant growth inhibition could not be demonOffprint requests to. M. Scheringa strated despite the use of different administration schedules [25] . Therefore we, and others, concluded that TNFc~ should be used in combination therapy, for example with other biological response modifiers, and it has indeed been demonstrated that combining TNFc~ with intefferon y or c~ results in synergistic antitumour effects [l, 3, 27, 39] .
Another suggested possibility of increasing the efficacy of exogenous TNFc~, is to administer it at the time that endogenous TNF~ is release& This therapy has been referred to as endogenous-exogenous therapy [9] . Examples of TNFcz-inducing agents are endotoxin (lipopolysaccharide) and OK432. The former is a strong TNFcz inducer but can hardly be used clinically because of severe toxicity, while the latter is a strong and far less toxic TNFc~ inducer [10, 26] .
In search for other TNFc~-inducing agents, the known interferon inducer bropirimine was tested in vivo. We examined whether it can cause TNFc~ release by measuring serum levels of TNF(z after intraperitoneal (i.p.) administration of bropirimine in rats. Furthermore, we examined the effect of bropirimine treatment on a colon carcinoma and a rhabdomyosarcoma as compared to TNFc~ treatment. Finally, we examined whether the antitumour effect of bropirimine could be blocked by pretreatment with rabbit anti-TNFo~ serum.
Materials and methods
Animals. Male rats of the inbred WAG (RT1 u) strain were obtained from Harlan-CPB (Austerlitz, The Netherlands). The animals were bred under specific-pathogen-free conditions and were 10-14 weeks old when used.
Tumours. A 1,2-dimethylhydrazine-induced, moderately differentiated colon adenocarcinoma (CC531) and a rbabdomysarcoma (R2K), transplantable in syngeneic WAG rats, were used [13, 19] . CC531 was maintained in vitro in RPMI-1640 medium supplemented with 5% fetal calf serum and R2K in Dulbecco's modified Eagle medium with 10% newborn calf serum (sera were screened for virus and Mycoplasma infections). The media were supplemented with l% penicillin (5000 IU/ml), 1% streptomycin (5000 gg/tal) and 1% L-glutamine (200 mM), all obtained from Gibco (Paisley, UK). Before use, the cells were trypsinized In vitro testing of tumour celI lines for response to TNF. Tumour cells were seeded at I x 104 cells/well in flat-bottomed 96-well microtiter plates (Costar, Cambridge, Mass.) in a final volume of 0.2 ml medium/weil, and incubated at 37 ° C in 5% CO2 for 48 h in the presence of different concentrations of recombinant murine tumour necrosis factor c~ (rMuTNFc0. Concentrations of rMuTNFcc were 0 U/tal, 50 U/ml, 100 U/tal and 5000 U/ml. Growth of turuour cells was measured using an MTT (3-4,5-dimethyl-thiazol-2-yl)-2,5-diphenyl tetrazolinrubromide assay (for details see [25] Biology, Geht, Belgium). The preparation was over 99% pure, containing less than 4 ng endotoxin/mg protein. 2-Amino-5-bromo-6-phenyl-4-pyrimidinone (bropirimine) was produced as reported previously [31] and provided by the Upjohn Company, Kalamazoo, Mich., USA. Rabbit anti-(mouse-recombinant TNFct) serum (RaTNFS) was prepared in our laboratory. Rabbits were three-times irnmunized with rMuTNFc~ in combination with Freund's adjuvants (25 gg rMuTNFcdimmunization, administered intracutaneously). Blood was collected 1 week after the last immunization, serum was stored and tested for anti-TNFct activity. RaTNFS had a neutralizing capacity of 100000 U/tal serum in the L929 bioassay (see next paragraph). In vivo 0.5 ml RaTNFS given intravenously (i. v.) protected rats against the lethal effect of 20 gg rMuTNFc~ given subsequently. Rats not pretreated with RaTNFS (n = 2) both died while pretreated rats (n = 2) survived after rMuTNFct administration without signs of toxicity. a In vivo sensitivity of tumours CC531 and R2K for rMuTNFc~ and bropirhnine. A sub-renal-capsule assay was performed in rats. Control rats received i.v. 1 ml HBSS on days 0, 2 and 4 and 1 ml phosphatebuffered saline i.p. on days 0 and 1 after tumour implantation. rMuTNFc~-treated rats received i. v. 4 ~tg rMuTNFct on days 0, 2 and 4; bropirimine-treated rats received i.p. 200 mg/kg bropirimine on days 0 and 1 after tumour implantation. Animals were sacfificed at day 7 and tumours were enucleated and weighed. Both rMuTNFct and bropirimine had a significant growth-inhibiting effect on tumour CC531 (P <0.01 and P <0.05 respectively). Growth of tumour R2K was significantly inhibited by bropifimine (P <0.01) but rMuTNFc~ did not inhibit growth of R2K * Significantly different from conlrol received Hanks balanced salt solution (HBSS) i.v. and phosphatebuffered saline i.p. (control treatment). Each treaunent was tested twice on both tumours. In order to study the TNFt~-inducing capacity of bropirimine, rats received 200 mg/kg of the drug i. p. on 2 consecutive days (the therapeutic regimen). During the second day blood samples were collected and serum was stored at -20 ° C. Blood samples were taken 5 min prior to the second bropirimine administration and after 1, 2, 3, 4 and 6 la. Control animals received HBSS i.p.
In another series of experiments, using the sub-renal-capsule assay model, we tested whether the antitumour effect of bropirimine against an in vivo proven TNF-sensitive tumour (CC531) could be blocked by pretreatment with 0.25 ml RaTNFS i.v. On days 0 and 1 the rats received 200 mg/kg bropirimine i.p. immediately after an i.v. injection of 0.25 HBSS, normal rabbit serum or RaTNFS.
Statistical analysis. For measurement of significance of difference in the sub-renal-capsul assay, the Wilcoxon's rank sum test was performed. For measurement of significance between control and bropirimine-treated groups in the TNFct-inducing experiments, Student's t-test was used for the various time points.
Results
TNFo~ assay. For measurement of TNF« in the serum samples of the rats a standard cytotoxicity assay for TNFa, using the L929 cell line, was performed. Cells were seeded at 5 x 105 cells/well (100 gl) in flat-bottomed 96-well microtiter plates in the presence of actinomycin-D (rinn concentration 1 gg/ml). Sera, 50 and 100 times diluted, were added (to a final volume of 200 gl) and after 20 h the cell survival was estimated by the colorimetric MTT assay. Absorbance was read at 515 nm. The TNFct concentrations were calculated by comparison with a standard curve.
Experimentaldesign. To test the sensitivity of CC531 and R2K for TNFct and bropirimine in vivo, a sub-renal-capsule assay [ 13, 25] was performed. In summary, a piece of tumour of about 10 mg is placed underneath the renn capsule of the rats, whereafter treatment is starte& After 1 week animals are sacrificed, tumours enucleated and subsequently weighed. (Table 1 ; results of one of the experiments is shown). Efficacy for both agents was of the same order of magnitude for colon cancer CC531.
In vitro sensitivity ofCC531 and R2K for rMuTNF~ B o t h cell lines w e r e r e l a t i v e l y i n s e n s i t i v e to t h e cytos t a t i c / c y t o l y t i c a c t i v i t y o f r M u T N F c~ as m e a s u r e d after 48 h i n c u b a t i o n (Fig. 1). r M u T N F c~ c a u s e d o n l y a m i n o r , t h o u g h s i g n i f i c a n t , r e d u c t i o n in t h e n u m b e r o f v i a b l e cells in b o t h cell lines at a c o n c e n t r a t i o n

In vivo TNF o~ induction by bropirimine
Administration of 200 mg bropirimine/kg i.p. on 2 consecutive days (the therapeutic regimen) resulted in a significant increase in TNFc~ serum levels. TNFo~ serum levels peaked 1 h after the second administration and remained significantly elevated for up to 6 h at least. Mean TNFc~ serum levels in controls were surprisingly high at 5 min because two of the control rats had unexplained high TNFo~ starting levels.
Blocking of the antitumour effect of bropirimine against CC531 in vivo by RaTNFS
In two experiments RaTNFS partially blocked the tumourgrowth-inhibiting effect of bropirimine on CC531 (Table  2 ). In the first experiment, the effect of bropirimine + RaTNFS was 59% of the effect of bropirimine + HBSS, while in the second experiment the effect of bropirimine + RaTNFS was 57% of the effect of bropirimine + normal rabbit serum.
Discussion
Although it has been described how bropirimine induces the release of lymphokines other than interferon [20] , its TNFo~-inducing capacity has never been emphasized before. This capacity could be very interesting in the light of its role in tumour therapy. So far, the antitumour effects of bropirimine were believed to be especially mediated by 1,3,4,5,5,5,6,6,6  12 0,0,1,9,13,13,14,18,19,21 , 22,22 12 5,7,7,7,10,14,14,14,17,17, 20,20 6 -2,-1,1,5,5,7 8 1,2,2,4,11,11,12,12 a In two separate experiments the effect of pretreatment with RaTNFS on the antitumour effect of bropirimine on tumor CC531 in a sub-renalcapsule assay was measured. Animals were pretreated with HBSS (control), normal rabbit serum (NRS) or rabbit anti-TNFc~ serum (0.5 ml i. v. just prior to treatment), and then treated with HBSS (control, 1 ml i. p.) or bropirimine (200 mg/kg i.p.) at days 0 and 1 after tumour implantation. After 7 days animals were sacrificed, tumours were enucleated and weighed and tumour growth was calcutated. In both experiments, groups treated with bropirimine, regardless of pretreatment, were significantly different from the HBSS-treated groups (P <0.01). In both experiments the groups pretreated with HBSS or NRS and subsequendy treated with bropirimine were significantly different from the groups pretreated with RaTNFS and treated with bropirimine (P <0.01) * Significantly different from control/control ** Significantly different from control/control and from control/bropirimine *** Significantly different from control/control and from NRS/bropirimine endogenous interferons, leading to increased natural killer (NK) cell and macrophage cytotoxicity [5, 12] . The results of this study suggest that endogenous TNFc~ can also be an important effector of bropirimine activity. In rats, 200 mg/kg bropirimine, given i.p. on 2 consecutive days, resulted in increased serum levels of TNF~. All rats in the bropirimine-treated group had high starting levels of serum TNFoq indicating that single bropirimine administration does also induce TNF release (TNFo~ serum levels were only measured after the second bropirimine administration). The high mean TNFo~ serum levels in the control group at 5 min were due to two of the control animals. These animals had persistently higher TNFo~ levels throughout the experiment than the other rats in the control group, in whose serum virtually no TNFc~ could be demonstrated. The tumour-growth-inhibiting effect of bropirimine against an in vivo proven TNFc~ sensitive tumour, could be reduced about 40% by pretreatment with rabbit anti-TNFc~ serum. This study shows that TNFc~ is only one of the mediators through which bropirimine exerts its antitumour effect, since the in vivo TNFc~-insensitive tumour R2K responded as well to bropirimine as did tumour CC531. Bropirimine has already been shown to be a potent immunotherapeutic agent against different types of experimental cancer [5, 16, 17] , which is confirmed by this study. Treatment with bropirimine often resulted not only in growth inhibition but even in tumour regression. Earlier observations in our laboratory have shown that bropirimine does not only inhibit growth of tumour CC531 in a subrenal-capsule assay but also in an artificial liver metastases model [6] .
The TNF(x-inducing capacity of bropirimine is the more interesting with regard to the so-called endogenousexogenous therapy. This therapy seems to have better antitumour efficacy than either induction of endogenous TNFc~ or administration of exogenous TNFc~ [9] . So far, endogenous-exogenous therapy has been performed using the streptococcal preparation OK432 as the TNFc(-inducing agent [26] . Like bropirimine, OK432 causes the release of TNFo~ [23] and it increases macrophage [23] , NK cell, [33] and large granular lymphocyte cytotoxicity [29] . It also induces the release of interferon [22] . Peak levels of TNF(x in serum of mice after OK432 treatment [24] were in the same order as peak levels of TNF~z in serum of rats after bropirimine treatment in this study. Although comparison of results obtained in rats or mice can never lead to final conclusions, bropirimine might well be an alternative to OK432 in endogenous-exogenous therapy. It has already been reported that bropirimine and TNFo~ have synergistic antitumour effects [13] .
This study emphasizes again that in vitro findings, as far as biological response modifiers are concerued, do not predict the in vivo outcome. Both tumours CC531 and R2K were in vitro relatively insensitive to the cytostatic/cytolytic activity of rMuTNFc~, but growth of tumour CC531 was strongly inhibited in vivo by treatment with rMuTNFo~.
The recognition of bropirimine as being a TNFc~ inducer in vivo may well explain a previously reported effect of the drug that could not be explained on the basis of its interferon-inducing capacity. It appeared that bropirimine could protect mice against listeriosis [2] . This protecting effect of the drug against an infection with Listeria monocytogenes, remained when the mice were pretreated with a potent anti-interferon antibody, indicating that this effect was not due to endogenous interferon. It is known that endogenous TNFc~ protects mice against infection with Listeria, especially in the early stages of the infection [7, 11] , so the protecting effect of bropirimine could well be mediated by endogenous TNFc~.
From the results presented in this study it can be concluded that bropirimine can induce the release of TNFc~ in rats; this endogenous TNFc~ can be important as rar as the antitumour effects of bropirimine are concerned and could make the drug an even more important, immunomodulatory, antitumor agent.
